Early Trial Data Suggest mRNA Vaccine Lowers Melanoma Recurrence Risk
Moderna and Merck released early phase 3 trial results after data circulated on social media. In 1,137 people with high-risk melanoma, adding a personalized mRNA vaccine to pembrolizumab lowered the risk of recurrence or death by 42% and the risk of distant spread or death by 38% compared with pembrolizumab alone over a median follow-up of about two years. Overall survival data are not yet available.
The phase 3 study enrolled 1,137 people with high-risk melanoma. The experimental arm combined pembrolizumab, which is designed to keep tumors from evading immune detection, with intismeran autogene, a personalized mRNA vaccine intended to teach the immune system to recognize and attack cancer.
After a median follow-up of roughly two years, the combination cut recurrence or death by 42% and distant spread or death by 38% versus pembrolizumab alone. Overall survival and quality-of-life findings are still pending; the early release followed a social-media leak, and the companies say the results have been accepted by the New England Journal of Medicine and that they are talking with regulators.
If approved, this approach could matter most to people with high-risk melanoma and their families, who may gain another option to delay recurrence. Clinicians and regulators may need to weigh the recurrence benefits against still-missing overall survival and quality-of-life data. Because the vaccine is personalized, access and delivery could become practical questions, though the current report does not address them.